research use only

AMG 232 ( KRT-232 ) MDM2/MDMX inhibitor

Cat.No.S7426

AMG 232 (Navtemadlin) is a potential, selective inhibitor of the MDM2–p53 interaction, with an IC50 of 0.6 nM and binds to MDM2 with a Kd of 0.045 nM. It also demonstrated antitumor activity in vivo in a variety of tumor types with different genetic backgrounds.
Jump to

Quality Control

Batch: Purity: 99.46%
99.46

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (175.88 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 568.55 Formula

C28H35Cl2NO5S

Storage (From the date of receipt)
CAS No. 1352066-68-2 Download SDF Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
p53-MDM2
0.045 nM(Kd)
p53-MDM2
0.6 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-11)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041688 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
2018-02-08 PHASE1
NCT04190550 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
National Cancer Institute (NCI)
2021-02-04 PHASE1
NCT03107780 TERMINATED
Glioblastoma; Gliosarcoma; MGMT-Unmethylated Glioblastoma; Recurrent Glioblastoma
National Cancer Institute (NCI)
2018-07-09 PHASE1
NCT04835584 UNKNOWN
Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
2021-05-07 PHASE1; PHASE2
NCT03787602 UNKNOWN
Merkel Cell Carcinoma
Kartos Therapeutics, Inc.
2019-03-19 PHASE1; PHASE2
NCT04669067 UNKNOWN
Acute Myeloid Leukemia
Telios Pharma, Inc.
2021-03-31 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map